{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:11:32Z","timestamp":1789384292319,"version":"build-2803163510"},"reference-count":45,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":3629,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.exphem.2012.04.004","type":"journal-article","created":{"date-parts":[[2012,4,25]],"date-time":"2012-04-25T02:31:00Z","timestamp":1335321060000},"page":"513-517","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["How can we reduce hepatic veno-occlusive disease\u2013related deaths after allogeneic stem cell transplantation?"],"prefix":"10.1016","volume":"40","author":[{"given":"Douglas B.","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bipin N.","family":"Savani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2012.04.004_bib1","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/hep.1840040121","article-title":"Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors","volume":"4","author":"McDonald","year":"1984","journal-title":"Hepatology"},{"key":"10.1016\/j.exphem.2012.04.004_bib2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","article-title":"Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients","volume":"118","author":"McDonald","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.exphem.2012.04.004_bib3","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/0360-3016(88)90009-0","article-title":"Venocclusive disease of the liver after allogeneic bone marrow transplantation in man","volume":"14","author":"Ganem","year":"1988","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.exphem.2012.04.004_bib4","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1053\/bbmt.2002.v8.pm12374451","article-title":"Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes","volume":"8","author":"Russell","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2012.04.004_bib5","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.bbmt.2008.03.009","article-title":"Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML\/MDS","volume":"14","author":"Andersson","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2012.04.004_bib6","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1182\/blood-2004-02-0414","article-title":"Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS","volume":"104","author":"de Lima","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.04.004_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2010.12.444","article-title":"Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation","author":"Perkins","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2012.04.004_bib8","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/sj.leu.2404334","article-title":"Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents","volume":"20","author":"Barrett","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2012.04.004_bib9","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.bbmt.2011.06.006","article-title":"The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade","volume":"17","author":"Carreras","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2012.04.004_bib10","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1182\/blood-2002-06-1860","article-title":"Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation","volume":"101","author":"McDonald","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.04.004_bib11","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/blood-2003-04-1311","article-title":"Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients","volume":"103","author":"Hogan","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.04.004_bib12","first-page":"3599","volume":"92","author":"Carreras","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.04.004_bib13","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.bbmt.2007.03.012","article-title":"Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality","volume":"13","author":"McCune","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2012.04.004_bib14","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/bmt.2009.153","article-title":"Prior treatment with gemtuzumab ozogamicin and the risk of veno-occlusive disease after allogeneic haematopoietic stem cell transplantation","volume":"45","author":"Chevallier","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2012.04.004_bib15","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bbmt.2009.08.024","article-title":"Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome","volume":"16","author":"Coppell","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2012.04.004_bib16","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/sj.bmt.1704943","article-title":"The hemochromatosis C282Y allele: a risk factor for hepatic veno-occlusive disease after hematopoietic stem cell transplantation","volume":"35","author":"Kallianpur","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2012.04.004_bib17","first-page":"4377","article-title":"Pharmacogenetic analysis of liver toxicity after busulfan\/cyclophosphamide-based allogeneic hematopoietic stem cell transplantation","volume":"27","author":"Goekkurt","year":"2007","journal-title":"Anticancer Res"},{"key":"10.1016\/j.exphem.2012.04.004_bib18","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/leu.2008.323","article-title":"Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia","volume":"23","author":"Rocha","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2012.04.004_bib19","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/sj.bjp.0704972","article-title":"Overexpression of glutathione S-transferase A1-1 in ECV 304 cells protects against busulfan mediated G2-arrest and induces tissue factor expression","volume":"137","author":"Ritter","year":"2002","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.exphem.2012.04.004_bib20","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1067\/mcp.2002.124518","article-title":"Genetic polymorphisms of glutathione S-transferase A1, the major glutathione S-transferase in human liver: consequences for enzyme expression and busulfan conjugation","volume":"71","author":"Bredschneider","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.exphem.2012.04.004_bib21","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-2036.2006.03001.x","article-title":"Review article: management of hepatic disease following haematopoietic cell transplant","volume":"24","author":"McDonald","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.exphem.2012.04.004_bib22","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1182\/blood.V89.6.2184","article-title":"Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation","volume":"89","author":"Salat","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.04.004_bib23","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s002770050364","article-title":"Endothelial dysfunction after bone marrow transplantation: increase of soluble thrombomodulin and plasminogen activator inhibitor\u22121 in patients with multiple transplant-related complications","volume":"76","author":"Nurnberger","year":"1998","journal-title":"Ann Hematol"},{"key":"10.1016\/j.exphem.2012.04.004_bib24","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1097\/00007890-199504150-00017","article-title":"Utility of transvenous liver biopsies and wedged hepatic venous pressure measurements in sixty marrow transplant recipients","volume":"59","author":"Shulman","year":"1995","journal-title":"Transplantation"},{"key":"10.1016\/j.exphem.2012.04.004_bib25","first-page":"1122","article-title":"Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study","volume":"111","author":"Chopra","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2012.04.004_bib26","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1182\/blood-2002-04-1216","article-title":"Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome","volume":"100","author":"Richardson","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.04.004_bib27","first-page":"906","article-title":"Defibrotide (DF) in the treatment of severe hepatic veno-occlusive disease (VOD) with multi-organ failure (MOF): results of a treatment IND expanded access protocol","volume":"116","author":"Richardson","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.exphem.2012.04.004_bib28","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood.V89.5.1501","article-title":"Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients","volume":"89","author":"Bearman","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.04.004_bib29","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1182\/blood.V76.9.1867.1867","article-title":"Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens","volume":"76","author":"Clift","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.04.004_bib30","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00277-004-0982-4","article-title":"Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation","volume":"84","author":"Lee","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1016\/j.exphem.2012.04.004_bib31","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/j.bbmt.2011.04.009","article-title":"Pretransplantation liver function impacts on the outcome of allogeneic hematopoietic stem cell transplantation: a study of 455 patients","volume":"17","author":"Barba","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2012.04.004_bib32","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.bbmt.2006.09.012","article-title":"Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation","volume":"13","author":"Tay","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2012.04.004_bib33","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.1840160213","article-title":"Immunomodulatory effects of ursodeoxycholic acid on immune responses","volume":"16","author":"Yoshikawa","year":"1992","journal-title":"Hepatology"},{"key":"10.1016\/j.exphem.2012.04.004_bib34","doi-asserted-by":"crossref","first-page":"975","DOI":"10.7326\/0003-4819-128-12_Part_1-199806150-00002","article-title":"Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial","volume":"128","author":"Essell","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.exphem.2012.04.004_bib35","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/sj.bmt.1703342","article-title":"A randomized trial of heparin plus ursodiol vs. heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation","volume":"29","author":"Park","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2012.04.004_bib36","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1182\/blood-2001-12-0159","article-title":"Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation","volume":"100","author":"Ruutu","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.04.004_bib37","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1002\/hep.23533","article-title":"Hepatobiliary complications of hematopoietic cell transplantation, 40 years on","volume":"51","author":"McDonald","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.exphem.2012.04.004_bib38","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/j.1365-2036.2005.02427.x","article-title":"A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis","volume":"21","author":"de Wet","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.exphem.2012.04.004_bib39","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1086\/423378","article-title":"A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis","volume":"39","author":"Krause","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"suppl 1","key":"10.1016\/j.exphem.2012.04.004_bib40","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1439-0507.2008.01524.x","article-title":"Comedication of caspofungin acetate and cyclosporine A after allogeneic haematopoietic stem cell transplantation leads to negligible hepatotoxicity","volume":"51","author":"Christopeit","year":"2008","journal-title":"Mycoses"},{"key":"10.1016\/j.exphem.2012.04.004_bib41","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.bbmt.2009.08.015","article-title":"Hepatic safety of voriconazole after allogeneic hematopoietic stem cell transplantation","volume":"16","author":"Amigues","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2012.04.004_bib42","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1592\/phco.28.12.1502","article-title":"Optimal prevention of seizures induced by high-dose busulfan","volume":"28","author":"Eberly","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.exphem.2012.04.004_bib43","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1600-0404.2008.01009.x","article-title":"Hepatotoxicity associated with antiepileptic drugs","volume":"118","author":"Bjornsson","year":"2008","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.exphem.2012.04.004_bib44","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1345\/aph.1Q087","article-title":"Busulfan and metronidazole: an often forgotten but significant drug interaction","volume":"45","author":"Gulbis","year":"2011","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.exphem.2012.04.004_bib45","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1600-0609.2010.01570.x","article-title":"Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells","volume":"86","author":"Giallongo","year":"2011","journal-title":"Eur J Haematol"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X12001385?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X12001385?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:29:45Z","timestamp":1759566585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X12001385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S0301472X12001385"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2012.04.004","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How can we reduce hepatic veno-occlusive disease\u2013related deaths after allogeneic stem cell transplantation?","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2012.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}